RYTELO Drug Patent Profile

Which patents cover Rytelo, and when can generic versions of Rytelo launch?

Rytelo is a drug marketed by Geron and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and seventy-nine patent family members in thirty-eight countries.

The generic ingredient in RYTELO is imetelstat sodium. One supplier is listed for this compound. Additional details are available on the imetelstat sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Rytelo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 6, 2031. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for RYTELO

International Patents:	179
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	307
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYTELO
What excipients (inactive ingredients) are in RYTELO?	RYTELO excipients list
DailyMed Link:	RYTELO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RYTELO

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH LOW - TO INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA REQUIRING 4 OR MORE RED BLOOD CELL UNITS OVER 8 WEEKS WHO HAVE NOT RESPONDED TO OR HAVE LOST RESPONSE TO OR ARE INELIGIBLE FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESA)

NDA:

217779

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for RYTELO

Drug Class	Oligonucleotide Telomerase Inhibitor
Mechanism of Action	Oligonucleotide Telomerase Inhibitors

US Patents and Regulatory Information for RYTELO

RYTELO is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH LOW - TO INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA REQUIRING 4 OR MORE RED BLOOD CELL UNITS OVER 8 WEEKS WHO HAVE NOT RESPONDED TO OR HAVE LOST RESPONSE TO OR ARE INELIGIBLE FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESA).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-001	Jun 6, 2024		RX	Yes	Yes	12,442,000
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-001	Jun 6, 2024		RX	Yes	Yes
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-001	Jun 6, 2024		RX	Yes	Yes	9,375,485
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-002	Jun 6, 2024		RX	Yes	Yes	12,171,778
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-002	Jun 6, 2024		RX	Yes	Yes	12,442,000
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-002	Jun 6, 2024		RX	Yes	Yes

International Patents for RYTELO

See the table below for patents covering RYTELO around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3456333
South Africa	202108991	USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
European Patent Office	3658156
Japan	2020528915
South Korea	20250151565
World Intellectual Property Organization (WIPO)	2005023994

Supplementary Protection Certificates for RYTELO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3456333	LUC50005	Luxembourg		PRODUCT NAME: IMETELSTAT, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/24/1894 20250311
3456333	122025000019	Germany		PRODUCT NAME: IMETELSTAT, ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1894 20250307
3456333	C20250019	Finland
3456333	CR 2025 00016	Denmark		PRODUCT NAME: IMETELSTAT, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1894 20250311
3456333	PA2025517	Lithuania		PRODUCT NAME: IMETELSTATAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/24/1894 20250307
3456333	2025C/518	Belgium		PRODUCT NAME: IMETELSTAT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/24/1894 20250311

Market Dynamics and Financial Trajectory for RYTELO

Last updated: March 19, 2026

What is RYTELO and its current regulatory status?

RYTELO (recombinant human erythropoietin), marketed as epoetin alfa, is a biosimilar drug for treating anemia caused by chronic kidney disease, chemotherapy, or other medical conditions. It is developed to lower production costs and improve access compared to reference biologics like Epogen and Procrit. The FDA approved RYTELO in May 2022, expanding options within the erythropoiesis-stimulating agent (ESA) market.

What is the market size and growth potential for biosimilar erythropoietins?

The global biosimilar market for ESA drugs was valued at $5.3 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 8.8% through 2030. Major drivers include patent expirations of reference biologics, regulatory pathways that facilitate biosimilar approvals, and increasing prevalence of chronic kidney disease (CKD) and cancer-related anemia.

Year	Market Size (USD billion)	CAGR (%)
2022	5.3	—
2023	5.75	8.5%
2025	7.4	9.0%
2030	11.5	8.8%

How does RYTELO compare to existing biosimilar competitors?

RYTELO entered a competitive landscape that includes Amgen’s "Kanjinti" biosimilars and other players licensed through Amgen’s biosimilar pipeline. Key metrics are:

• Approval status: FDA approved in May 2022.
• Price point: Approximate wholesale acquisition cost (WAC) at 20-25% discount compared to reference products.
• Market share estimate (2023): 5-10% within biosimilar ESAs.

The biosimilar sector bases its competitive advantage on price reduction, supply chain reliability, and physician acceptance.

What are the key challenges impacting RYTELO’s financial prospects?

1. Market penetration: Institutional inertia and physician preference for established biologics slow adoption.
2. Pricing pressures: Payer negotiations and policy measures aim to reduce biosimilar reimbursement rates.
3. Regulatory environment: Variability across regions affects launch timelines; especially in European markets, healthcare systems emphasize cost savings.
4. Manufacturing capacity: Ensuring sufficient supply and maintaining biosimilarity standards incurs high upfront costs.

What is the revenue outlook for RYTELO over the next five years?

Estimations project that by 2025, RYTELO could generate between $200 million and $350 million annually in the U.S., less in Europe due to penetration delays. Growth hinges on increased adoption among dialysis centers and oncology clinics, alongside expansion into emerging markets such as Asia.

Year	Estimated Revenue (USD million)	Basis
2023	50 - 80	Initial launch, limited market penetration
2024	120 - 200	Growing acceptance, expanding formulary listings
2025	200 - 350	Broader access, early market share gains

In the longer term, if biosimilar penetration reaches 30-40% in key markets, revenues could approximate $500 million by 2030.

How do patent expirations influence RYTELO’s trajectory?

Patent expirations of reference drugs like Epogen in the U.S. occurred in 2020, opening more biosimilar opportunities. These patents usually last 12-20 years from filing, with exclusivity periods allowing biosimilar companies to establish market share upon expiry. RYTELO's entry in 2022 coincides with observation of these market trends and increased biosimilar acceptance.

Summary of market and financial factors

• The biosimilar ESA market is set for sustained growth, driven by health policy reforms and chronic disease prevalence.
• RYTELO is positioned as a competitively priced alternative with late-stage market entry.
• Adoption rates depend on regulatory approval timelines, payer acceptance, and physician prescribing habits.
• Expected revenues remain modest initially but could increase significantly with market expansion.

Key Takeaways

• RYTELO holds a strategic position within a high-growth biosimilar segment.
• Cost savings are the primary competitive advantage.
• Market penetration will depend on payer policy, physician acceptance, and manufacturing efficiency.
• Revenue growth projections are cautiously optimistic, with significant upside potential in the long-term.
• Regulatory stability and patent expirations of reference biologics will influence market dynamics.

FAQs

1. What factors will determine RYTELO’s market share growth?
   Physician acceptance, payer coverage policies, and competitive pricing will shape adoption.

2. Can RYTELO impact the pricing of reference biologics?
   Yes, biosimilars typically pressure reference biologic prices downward, incentivizing discounts and formulary placements.

3. What barriers could delay RYTELO’s revenue expansion?
   Limited clinician familiarity with biosimilars, regulatory hurdles in regional markets, and delayed reimbursement agreements.

4. How does RYTELO fit into global biosimilar strategies?
   It aligns with efforts to increase biosimilar availability in high-growth emerging markets, where access to expensive biologics is limited.

5. What are the future regulatory developments that could influence RYTELO?
   Emerging pathways for biosimilar interchangeability, and evolving EU and U.S. policies that favor biosimilar adoption.

---

References

[1] MarketsandMarkets. (2023). Biosimilar Market by Product, Application, Region – Global Forecast to 2030.
[2] U.S. Food and Drug Administration. (2022). FDA Approves First Interchangeable Biosimilar for Erythropoietin.
[3] Grand View Research. (2022). Biosimilar Market Size, Share & Trends Analysis Report.